|
|
Article: Rabeprazole Delayed Release Tablets (Aciphex-Eisai Inc. and Janssen Pharmaceutic.
- Article from:
- Internal Medicine Alert
- Article date:
- September 29, 1999
CopyrightCOPYRIGHT 1999 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pharmacology Update
Rabeprazole Delayed Release Tablets (AciphexEisai Inc. and Janssen Pharmaceutica)
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
The fda has approved a third proton pump inhibitor (PPI) for the treatment of duodenal ulcers and gastroesophageal reflux disease (GERD). Rabeprazole (Aciphex) joins omeprazole (Prilosec) and lansoprazole (Prevacid) in this competitive, $3 billion worldwide market. Rabeprazole will be comarketed in this country by Eisai Inc and Janssen Pharmaceutica. The drug is a pyridyl methysulfinyl benzaminidazole, chemically similar to omeprazole. The PPIs inhibit gastric acid secretion by ...